MYC
Myc proto-oncogene protein
Also known as: bHLHe39, c-Myc, MYC_HUMAN, MYCC
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P01106
- Gene
- MYC
- Ensembl
- ENSG00000136997
- Chromosome
- 8
- Canonical length
- 454 aa
- Protein class
- Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini. [provided by RefSeq, Aug 2017]
Canonical amino-acid sequenceUniProt
454 residues, UniProt reviewed canonical sequence.
>P01106|MYC
1 MDFFRVVENQ QPPATMPLNV SFTNRNYDLD YDSVQPYFYC DEEENFYQQQ QQSELQPPAP
61 SEDIWKKFEL LPTPPLSPSR RSGLCSPSYV AVTPFSLRGD NDGGGGSFST ADQLEMVTEL
121 LGGDMVNQSF ICDPDDETFI KNIIIQDCMW SGFSAAAKLV SEKLASYQAA RKDSGSPNPA
181 RGHSVCSTSS LYLQDLSAAA SECIDPSVVF PYPLNDSSSP KSCASQDSSA FSPSSDSLLS
241 STESSPQGSP EPLVLHEETP PTTSSDSEEE QEDEEEIDVV SVEKRQAPGK RSESGSPSAG
301 GHSKPPHSPL VLKRCHVSTH QHNYAAPPST RKDYPAAKRV KLDSVRVLRQ ISNNRKCTSP
361 RSSDTEENVK RRTHNVLERQ RRNELKRSFF ALRDQIPELE NNEKAPKVVI LKKATAYILS
421 VQAEEQKLIS EEDLLRKRRE QLKHKLEQLR NSCALocalizationUniProt · AlphaFold · HPA
Whether an antibody against MYC can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.64
- Highest tissue expression
- 277 nTPM
Expression across tissuesHPA
Tissue
- skin: 277 nTPM
- adipose tissue: 251 nTPM
- fallopian tube: 131 nTPM
- breast: 114 nTPM
- esophagus: 97 nTPM
- vagina: 93 nTPM
Single-cell type
- decidual stromal cells: 1,089 nCPM
- basal keratinocytes: 745 nCPM
- suprabasal keratinocytes: 719 nCPM
- breast secretory cells: 398 nCPM
- esophageal basal cells: 309 nCPM
- pericytes: 283 nCPM
Immune cell
- naive CD4 T-cell: 199 nTPM
- MAIT T-cell: 165 nTPM
- naive CD8 T-cell: 131 nTPM
- memory CD4 T-cell: 116 nTPM
- T-reg: 97 nTPM
- memory B-cell: 94 nTPM
Brain region
- medulla oblongata: 20 nTPM
- hypothalamus: 14 nTPM
- pons: 13 nTPM
- thalamus: 12 nTPM
- midbrain: 11 nTPM
- spinal cord: 10 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MYC.
Disease | AllUniProt
Conditions MYC is implicated in, by any mechanism.
- Burkitt lymphoma (BL) MIM:113970
Disease | GeneticClinVar
4 pathogenic / likely-pathogenic of 47 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Burkitt lymphoma
- Acute myeloid leukemia
ReferencesPubMed · IEDB
Publications for MYC from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
4 publications
- Plasma anti-BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer.
2018 · FEBS Open Bio · RCR 0.6 · 15 citations - Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer.
2015 · FEBS Open Bio · RCR 0.3 · 11 citations - Study of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer.
2015 · FEBS Open Bio · RCR 0.1 · 6 citations - Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma.
2025 · Adv Med Sci
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.16
- gnomAD pLI
- 1
- gnomAD missense Z
- 1.22
- DepMap mean gene effect
- -1.74
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- B cell apoptotic process
- branching involved in ureteric bud morphogenesis
- cellular response to hypoxia
- cellular response to interferon-alpha
- cellular response to UV
- cellular response to xenobiotic stimulus
- chromatin remodeling
- chromosome organization
- detection of mechanical stimulus involved in sensory perception of sound
- DNA damage response
- ERK1 and ERK2 cascade
- fibroblast apoptotic process
- G1/S transition of mitotic cell cycle
- intracellular iron ion homeostasis
- intrinsic apoptotic signaling pathway in response to DNA damage
- MAPK cascade
- middle ear morphogenesis
- myotube differentiation
- negative regulation of apoptotic process
- negative regulation of cell division
- negative regulation of fibroblast proliferation
- negative regulation of gene expression via chromosomal CpG island methylation
- negative regulation of monocyte differentiation
- negative regulation of stress-activated MAPK cascade
- negative regulation of transcription by RNA polymerase II
- negative regulation of transcription initiation by RNA polymerase II
- NK T cell proliferation
- pigmentation
- positive regulation of B cell apoptotic process
- positive regulation of cell population proliferation
- positive regulation of DNA-templated transcription
- positive regulation of epithelial cell proliferation
- positive regulation of fibroblast proliferation
- positive regulation of gene expression
- positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator
- positive regulation of mesenchymal cell proliferation
- positive regulation of miRNA transcription
- positive regulation of telomere maintenance
- positive regulation of transcription by RNA polymerase II
- positive regulation of transcription initiation by RNA polymerase II
- protein processing
- protein-DNA complex disassembly
- regulation of cell cycle process
- regulation of gene expression
- regulation of somatic stem cell population maintenance
- regulation of telomere maintenance
- regulation of transcription by RNA polymerase II
- response to alkaloid
- response to growth factor
- response to xenobiotic stimulus
- rRNA metabolic process
- skeletal muscle cell differentiation
- skeletal system morphogenesis
- transcription by RNA polymerase II
- Wnt signaling pathway
- acinar cell proliferation
- positive regulation of acinar cell proliferation
- positive regulation of metanephric cap mesenchymal cell proliferation
Molecular functions
- core promoter sequence-specific DNA binding
- DNA binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA-binding transcription factor binding
- DNA-binding transcription repressor activity, RNA polymerase II-specific
- E-box binding
- identical protein binding
- protein dimerization activity
- protein-containing complex binding
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- transcription coregulator binding
- transcription regulator activator activity
- ubiquitin protein ligase binding
- SCF ubiquitin ligase complex binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MYC in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MYC as an antibody target. Whether an autoantibody or antibody against MYC could matter depends on whether native MYC is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MYC is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MYC as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...